Biogen Inc (BIIB)

[XenaLives]

Eisai needs a new partner.

The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain

First late-stage study data successfully demonstrating potential disease-modifying effects on both clinical function and amyloid beta accumulation in the brain

New data provide compelling evidence to further support amyloid hypothesis as a therapeutic target for Alzheimer’s disease

https://globenewswire.com/news-release/2018/07/05/1533998/0/en/Eisai-and-Biogen-Announce-Positive-Topline-Results-of-the-Final-Analysis-for-BAN2401-at-18-Months.html